WILMINGTON, MA —
Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has been issued patent # 8,173,959 from the U.S. Patent and Trademark Office. The patent, “Real-Time Trace Detection by High Field and Low Field Ion Mobility and Mass Spectrometry,” covers a method for a hyphenated trace detection employing a combination of ion mobility spectrometry, differential mobility spectrometry, and mass spectrometry. This marks the thirteenth patent Implant Sciences has been issued and the third it has received in fiscal 2012.
Implant Sciences’ latest patent focuses on the real-time detection, identification and analysis of trace amounts of narcotics, explosives and chemical agents.
Todd Silvestri, Implant Sciences’ Vice President of Technology, stated, “We believe the technology described in this patent will define the next generation of trace detection equipment. Systems incorporating this invention will be able to detect a wider range of threats with greater accuracy and fewer false alarms while maintaining the advantages of IMS throughput.”
“Mass Spectrometry has been a promising technology in trace detection for more than a decade,” added Implant Sciences’ Chief Operating Officer, Dr. Bill McGann. “The time for implementation is now, and the benefits for expanding the range of detection will greatly enhance global security. Turning credible science into practical technology through innovation is a cornerstone of the Implant Sciences global strategy.”
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SSD) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company’s QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing Evaluation (DTE) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com
Safe Harbor Statement
This press release may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management’s current expectations and assumptions which could differ materially from the forward-looking statements.
© Marketwire 2012